line 18: after "cells", insert --(B5/589); immortalized bronchial epithelial cells-~;

line 21: delete "AG1523", insert --(AG1523)--;

line 21: delete "AG1523", insert --(AG1523)--.

Page 75, line 22 through page 79, end, delete entire section entitled "REFERENCES FOR EXPERIMENTAL SECTION II".

**IN THE CLAIMS:**

Please cancel claim 1 and add the following new claims:

--21. A method of treating conditions requiring specific stimulation of epithelial cells comprising administering an epithelial cell stimulating amount of substantially pure human KGF polypeptide that is characterized by a molecular weight between 16 and 30 kDa and a specific activity of at least about $3.4 \times 10^4$ units per milligram of protein.

22. A method according to Claim 21 wherein the polypeptide has a molecular weight between 16 and 22 kDa and a specific activity of at least about $3.4 \times 10^4$ units per milligram of protein.

23. A method according to Claim 22 wherein the polypeptide comprises the amino acid sequence presented in Figure II-[I]1B wherein the N-terminus is cysteine 32 and the C-terminus is threonine 194.

24. A method according to Claim 21 wherein the polypeptide is administered as a pharmaceutical composition comprising human KGF as presented in Figure II-1B wherein the N-terminus is cysteine 32 and the C-terminus is threonine 194 and an acceptable pharmaceutical carrier.

Sub C2 Cont.

25. A method of treating conditions requiring specific stimulation of epithelial cells comprising administering an epithelial cell stimulating amount of a substantially pure chimeric polypeptide, wherein said chimeric polypeptide comprises a functional domain of human KGF and a polypeptide of a different member of the fibroblast growth factor (FGF) family.

26. A method of accelerating or improving wound healing involving the epidermis, the method comprising administering to the wound site, an epithelial cell stimulating amount of a pharmaceutical composition comprising:

(a) a substantially pure human keratinocyte growth factor (KGF) polypeptide characterized by a molecular weight between 16 and 30 kDa and a specific activity of at least about $3.4 \times 10^4$ units per milligram of protein; and

B 17 Cont.

(b) an acceptable pharmaceutical carrier.

27. A method of treating conditions requiring specific inhibition of epithelial cells, the method comprising administering an epithelial cell inhibiting amount of pharmaceutical composition, wherein said pharmaceutical composition comprises an antibody against a polypeptide selected from the group consisting of a polypeptide comprising a unique portion of an amino acid sequence in Figure II-1B, a polypeptide comprising an amino acid sequence as presented in Figure II-1B wherein the N-terminus is cysteine 32 and the C-terminus is threonine 194, and a polypeptide comprising an allelic variant of human KGF.